Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTH-300: APL-130277 in PD OFF Episodes
NCT02469090Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of apomorphine in Parkinson's disease (PD), sponsored by Sumitomo Pharma America. Started Jun 2015; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02469090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469090.